With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-270-Universal Health Service

The company provides hospital and health care services in the United States, United Kingdom, and Puerto Rico, operating more than 400 acute care hospitals and other facilities.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-281-Universal-Health-Services

The medical management company operates 400 clinics and other health care facilities across the U.S. and U.K.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Universal Health Services is one of the largest providers of hospitals and health care services in the U.S. Since its founding in 1979, the health care giant operates more than 400 acute-care hospitals, behavioral health facilities, emergency departments, and ambulatory surgery centers across the U.S. and the United Kingdom. Universal Health Services also offers an insurance plan, the Prominence Health Plan, including Medicare Advantage plans for members in Florida, Nevada, and Texas. The company served over 3.5 million patients in 2024, operating with nearly 100,000 employees globally. In 2024, the company was ranked by Fortune as one of the World’s Most Admired Companies.

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Universal Health Services (UHS): Company Profile, Stock Price, News, Rankings

legacy

Universal Health Services

universal health services

Good day, and thank you for standing by. Welcome to the Q3 2026 Universal Health Services earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Darren Lehrich, Vice President of Investor Relations. Please go ahead.

Good morning, and welcome to Universal Health Services' third quarter 2026 earnings conference call. I am Darren Lehrich, Vice President of Investor Relations. With me this morning are our President and CEO, Marc Miller, and our Chief Financial Officer, Steve Filton. Marc and Steve will offer some remarks about the quarter, and then we will open up to Q&A. During today's conference call, we will be using words such as believes, expects, anticipates, estimates, and similar words that represent forecast projections and forward-looking statements. For anyone not familiar with the risks and uncertainties inherent in these forward-looking statements, we recommend a careful reading of the section on risk factors and forward-looking statements and risk factors in our Form 10-K for the year ended December 31st, 2025, and in our Form 10-Q for the quarter ended June 30, 2026.

In addition, we may reference measures during today's call, such as EBITDA, adjusted EBITDA, adjusted EBITDA net of NCI, and adjusted net income attributable to UHS, which are non-GAAP financial measures. Information and reconciliations of these non-GAAP financial measures to net income attributable to UHS can be found in yesterday's press release and in our supplemental materials on our website. With that, let me now turn it over to Marc for some introductory remarks.

Thank you, Darren. Good morning, and thank you for joining today's call. I will begin with our key takeaways from the quarter, performance relative to our expectations, the principal operating drivers, and progress on our strategic priorities before Steve reviews the detailed financial results and our outlook. Overall, underlying performance in the third quarter reflected sequential improvement in several acute care demand remained behavioral health volumes demonstrated an increase relative to recent quarters, and labor trends continued to moderate. Expense management remained disciplined overall. Health insurance exchange trends were consistent with our expectations. Steve will provide the reported financial results and segment metrics in his remarks. Third quarter results included certain items that were not reflected in the outlook we provided with our second quarter results in July.

These items included the benefit from the expansion of existing Medicaid supplemental programs in several states, partially offset by other non-recurring litigation and transaction costs, which Steve will take you through in a moment. Against that backdrop, I want to highlight three operating and strategic priorities: acute care capacity and outpatient access points, integrating Talkspace, and advancing the recertification process at Laurel Ridge Treatment Center in Texas. First, our recent investments acute care inpatient capacity helped us meet favorable demand in our markets. The additional 177 beds added during the second quarter are expected to continue ramping through year-end. We also expanded our outpatient portfolio by opening one freestanding emergency department in the third quarter and another FED that recently opened during the fourth quarter. In addition, our ambulatory development pipeline is expected to add several outpatient access points over the coming quarters.

The key takeaway is that these investments are performing well, broadening access, and supporting growth. We expect their contribution to build over time as the new capacity matures. Second, behavioral health, we completed the Talkspace acquisition on August 17 and began executing the integration plan. We intend to discuss anticipated synergies in greater detail when we provide 2027 guidance in February. For the balance of 2026, we are taking a phased approach centered on three integration workstreams. The first, deploying a technology platform and tools that enable smoother transitions of care and greater continuity of outpatient care for UHS patients. Number two, establishing referral flow processes to Talkspace from behavioral health acute care facilities for both individual therapy and medication management services.

And three, developing more flexible market-based outpatient offerings, initially emphasizing a virtual intensive outpatient program or IOP, offerings designed to address strong demand in this area. We expect these initiatives to support the acquisition's long-term benefits over the next 12-24 months. Our priorities are to expand access to outpatient mental health services and strengthen our outpatient growth profile. The key takeaway is that our integration is underway, and the expected benefits will develop in phases as technology, new referral pathways, and service offerings are enhanced through our integration efforts. We will provide further updates as the integration progresses and the rollout expands across our operations. Third, at Laurel Ridge, our San Antonio team continues to work productively with regulatory authorities and the local community towards recertification, which we currently expect during 2027. The facility's third quarter financial impact was consistent with the assumptions in our updated July outlook.

In closing, I want to thank the UHS team for its continued dedication to our mission to provide quality care. Our strategy remains consistent, invest in attractive markets, expand access to care, operate efficiently, and create long-term value for patients, employees, and shareholders. We remain mindful of execution requirements and the ever-evolving operating environment, and we believe the strength of our portfolio, the experience of our management team, and underlying demand in our markets, continue to position us well over the long term. With that, I will turn the call over to Steve for additional detail on the quarter.

Thanks, Marc. I will organize my remarks in four parts: reported results and unusual items, segment performance, cash flow and capital allocation, and our 2026 outlook. Starting with reported results, the company reported adjusted EPS of $5.22 for the third quarter of 2026, representing a decline of 8% year-over-year. Third quarter adjusted EBITDA less NCI was $625 million as compared to $671 million in the third quarter of 2025. The net out-of-period DPP headwind in the quarter was $37 million when considering amounts recognized for the Washington, D.C. program approved in the third quarter of 2025, netted against out-of-period amounts recognized in this year's third quarter. To distinguish reported results from underlying performance in the third quarter of 2026, three specific items not contemplated in our annual adjusted EBITDA less NCI guidance provided in July, produced a net favorable impact of $12 million.

These items were $47 million of supplemental Medicaid benefits, not included in our July forecast, $26 million of additional professional and general liability reserves, primarily associated with the tentative settlement of a litigation matter related to our Cumberland facility in Virginia, and $8.5 million of transaction-related costs associated with the Talkspace acquisition. Excluding these items, adjusted EBITDA less NCI was below our internal expectations despite modest sequential improvement. The shortfall primarily reflected a slower than expected ramp-up at our de novo hospitals and softer than expected surgical trends. Turning to segment performance. On a same-facility basis, adjusted admissions at acute care hospitals increased 4.9% compared with the third quarter of 2025. Volume performance was broad-based geographically and also benefited from capacity additions at three hospitals during the second quarter of 2026.

 acute care emergency department visits increased 4.6%, while same-facility surgeries decreased 0.7% compared with the third quarter of 2025. Inpatient and outpatient surgical cases declined at similar levels in the quarter. Inpatient medical admissions significantly outpaced surgical admissions, which negatively skewed pricing trends in the quarter. By service line, we experienced strength in cardiology, neurology, and urology similar to recent quarters. By payer class, adjusted admissions growth for Medicare and Managed Medicare was above acute care segment average. Volume growth for Medicaid, Managed Medicaid, and Managed Care, excluding exchanges, was positive in the quarter, although below the segment average. On a same-facility basis, net revenue in acute care segment during the third quarter of 2026 increased 4.7%. Excluding the impact of our health plan, acute care net revenue increased 3.1%.

acute care same-facility revenue per adjusted admission decreased by 1.7% during the third quarter of 2026 on a reported basis and was slightly positive when excluding the net headwind from out-of-period Medicaid supplemental benefits and the shift in exchange to uninsured volumes. We estimate acute care rate growth was approximately 3% and consistent with recent quarters after adjusting for these factors and normalizing for the higher inpatient medical versus surgical mix. Operating expenses continued to be well managed across labor, supply, and other expense categories. acute care salaries, wages, and benefits expense per adjusted admission increased 2.1%, and supply expense per adjusted admission decreased 2.3% over last year's third quarter. Other operating expenses increased primarily due to our health plan, which experienced revenue growth of approximately 25% in the third quarter.

 acute care segment EBITDA declined 4.5% in the third quarter of 2026. Excluding the out-of-period supplemental program benefit from both periods, third quarter acute care segment EBITDA increased 2.9%. In acute care segment, the net out-of-period headwind related to supplemental payments was $29 million, comprised of $26 million in the third quarter of 2026 from expanded funding under existing programs, primarily in Washington, D.C., and California, compared with $55 million of out-of-period amounts in the third quarter of 2025 related to the Washington, D.C., program approved last year. For the third quarter of 2026, we estimate that health insurance exchange trends had an impact of slightly less than $25 million, which was consistent with the updated outlook provided in July. Exchange volumes declined 17% from the third quarter of 2025, accompanied by a similar increase in the number of self-pay volumes.

At Palm Beach Gardens, acute care de novo hospital remains in the early stages of ramping volumes across multiple service lines. Startup losses improved each month during the third quarter. While the ramp at this facility remains gradual, the progression supports our expectation for continued improvement as we enter Florida's seasonally busier winter period. In Washington, D.C., Cedar Hill Regional Medical Center operating losses were similar on a sequential basis, excluding supplemental payments. We continue to support the build-out of primary care and specialty physician practices in the community around the hospital and in our MOB. Because these practices remain at varying stages of developing their patient bases within the community, we now expect the hospital to reach operational break even in the first half of 2027, compared with our prior expectations of the fourth quarter of 2026.

Taken together, Palm Beach Gardens and Cedar Hill are progressing, but their pace of maturation remains an important factor in the timing of margin improvement for acute care segment. Turning behavioral health, third quarter same-facility net revenue increased 4.0%, supported by a 2.1% increase in same-facility revenue per adjusted patient day and a 2.1% increase in same-facility adjusted patient days. Volumes improved modestly compared with recent quarters, reflecting steady demand and greater emphasis on the continuum of outpatient levels of care. Included in our behavioral health segment results are Talkspace and an acquisition we completed in our U.K. operations in July, offset by startup losses associated with two de novo projects and ongoing operating losses at Laurel Ridge while we work towards recertification. Given the mid-quarter closing, Talkspace's contribution to third-quarter earnings was immaterial.

In behavioral health segment, the net out-of-period headwind related to supplemental payments was approximately $8 million in the third quarter of 2026, due primarily to the new Washington, D.C., program benefit in the third quarter of 2025. For the third quarter of behavioral health segment same-facility salaries, wages, and benefits per adjusted patient day increased 3.6% over the prior year, improving further on a sequential basis due to continued moderation in headcount growth. Turning to cash flow and capital allocation, third quarter cash generated from operating activities was $637 million, compared with $381 million during the same period last year. During the third quarter of 2026, we spent $214 million on capital expenditures, and we anticipate capital expenditures to be slightly below $1 billion for the full-year of 2026.

As several acute care de novo and expansion projects are now completed, we expect CapEx to moderate towards $800 million beyond 2026. During the third quarter of 2026, we acquired 1.35 million of our own shares at a total cost of $242 million, bringing year-to-date share repurchases to a total of $690 million. As of September 30, 2026, we had $735 million repurchase authorization available pursuant to our stock buyback program, and we expect to remain active with share repurchase for the foreseeable future. From a balance sheet perspective, we ended the quarter with cash of $169 million, total debt of $5.7 billion and leverage of 2.17x. Total debt reflects the August refinancing of our September 2026 debt maturity and incremental borrowings associated with the Talkspace acquisition.

As of September 30, 2026, we had approximately $1.2 billion of additional borrowing capacity available pursuant to our revolving credit facility. We remain committed to maintaining leverage within our target range of 2x-3x. Finally, turning to our 2026 outlook, we are reiterating the financial and operating forecast ranges issued with our second quarter results in July. Based on year-to-date trends through the third quarter and the ongoing ramp of acute care hospitals in Washington, D.C., and Palm Beach Gardens Hospital, Florida, we currently expect results to be towards the lower end of these ranges. The reiterated ranges reflect continued underlying operating improvement, balanced against the pace of de novo facility ramp-ups and the other near-term variables discussed today. Operator, that concludes our prepared remarks, and we would be pleased to answer questions at this time.

Thank you. We will now open the call to question-and-answers. To allow as many people as possible to submit a question, please limit yourself to one question and one follow-up. Our first question comes from the line of AJ Rice of UBS. Your line is now open.

Thanks. Hi, everybody. I know it is early to be talking about 2027, but some of the companies are, so I will ask it of you. At least, how do you think about puts and takes for next year? I guess specifically I can ask you on DPP headwinds, supplemental payment headwinds next year, given some out-of-period recognition this year, and early thoughts on incremental public exchange headwind, if any.

Yeah. I would just remind everybody, AJ, that consistent with prior years, we plan to issue our full comprehensive 2027 guidance in February when we report our fourth quarter results. We feel good about the core elements of our 2026 growth algorithm guidance in both segments, which we went through last quarter. Outside of that, we can point to a few items, a couple of which you mentioned, in terms of material headwinds and tailwinds as we begin to think about 2027. The biggest swing factors, I think, in 2027 relate to improvements at facilities that are incurring operating losses during 2026, particularly the Laurel Ridge San Antonio facility that we talked about and the acute care de novos that we mentioned in our prepared remarks.

Cumulatively, these facilities are expected to contribute operating losses of $80 million-$100 million in 2026, and we believe there is potential to recover at least a meaningful portion of those losses in 2027 as we anticipate making further operational progress at the de novo facilities over the next several quarters and regaining certification at the San Antonio facility. As it relates to San Antonio, I would just note we're making progress towards recertification and remain confident that we'll achieve that in 2027, giving us a path to rebuild census in a deliberate manner. On the headwind side, and I think you mentioned a couple of these things, the biggest swing factors relate to regulatory changes that continue to play out in the operating environment, particularly the impact from the exchanges, the potential impact of Medicaid work requirements, and the initial impact of reductions to Medicaid supplemental funding.

We also had a material amount of prior year DPP benefit in calendar year 2026 that will not repeat in 2027. As it relates to Medicaid supplemental payments, we estimate the 2027 headwind will be approximately $175 million-$200 million. This primarily includes prior year amounts that we recorded in 2026 for DPP programs in Florida, Nevada, Ohio, California, and Washington, D.C., as well as approximately $10 million of impact during the fourth quarter 2027 from the initial provider tax portion of the OB3 funding cuts. As it relates to the exchanges, annualizing the second half 2026 run rate would create a $15 million headwind in 2027. Further changes in exchange enrollment could increase that number, and we'll have greater insight into that following the open enrollment period.

As it relates to Medicaid work requirements, it's difficult to provide an estimate on the potential impact because the implementation timing may lag up to six months in certain states. More importantly, the state-specific regulatory guidance related to the medical frailty exceptions remains a key open item. Our baseline assumption is that the impact of Medicaid work requirements will be primarily concentrated in Medicaid expansion states, and that a vast majority behavioral health patients and a meaningful portion of acute care patients could be exempt from work requirements because their diagnoses meet the medical frailty exemption. As investors develop estimates on work requirements, it's worth noting from a volume perspective, Medicaid volumes in expansion states represented approximately 15% of our acute care segment adjusted admissions and 30% of behavioral health segment patient days.

Broadly, I think as most investors know, Medicaid revenue per unit of volume is lower than other payers. So as you do those calculations, you should keep those in mind.

Oh, that is very helpful. Thanks for that. Maybe just a follow-up. You have had very strong volumes. Obviously, it has been a shift, it looks like, to medical from surgical. I wondered if you could drill down just and talk a little bit about service lines. What has been strong on the medical side, and are you attributing the softness in surgery mainly to public exchange disenrollment or economy or something else?

Yeah, I think from our perspective, AJ, the trend towards a slightly weaker surgical mix is an acceleration of existing trends that we have seen for some time. That is the continued shift of procedures, both in and outpatient procedures, out of the hospital, in and outpatient services, and into alternative settings, whether they are ASCs or physician offices. We really see this in particular in certain service lines. GI, as an example, we have seen just an accelerated shift of procedures, both in and outpatient, into alternative settings and out of the hospital. A number of orthopedic procedures as well. We mentioned in our prepared remarks some of the service lines that have been performing fairly robustly. Those included cardiology, neurology, and urology. But yeah, I think, again, in our minds, what we are just seeing is this accelerated shift of procedures into these alternative settings.

Thank you. Our next question comes from the line of Ann Hynes of Mizuho. Your line is now open.

Great. Thank you. Just the two acute facilities that are not ramping as you thought. What is driving that slower ramp? Is there anything structural or challenges that you face? I have been covering the company for a long time, and I do not remember a time where the acute care hospitals are ramping below expectations. If you can just go into each market and what is driving the loss versus your expectations, that would be great. Thank you.

Yeah. I will address Cedar Hill first. Cedar Hill in Washington, D.C., opened in April of 2025. I think as we have been commenting consistently since that opening, it opened with a busy emergency room activity, and emergency room activity has remained busy since its opening. What has lagged has been a busier surgical and procedural schedule. I think the reason for that primarily is a lack of physician infrastructure in that part of the Washington, D.C., market. For years, and this is for those of you familiar with Washington, D.C., and Ward 7 and 8, there was really a lack of quality healthcare, and patients were leaving Ward 7 and 8 to get their healthcare elsewhere in the city. As a consequence, doctors really were not locating in Ward 7 and 8. Doctor offices were not.

As we indicated in our prepared remarks, we have addressed that by working with a number of different physicians and physician groups to establish practices in Ward 7 and 8, within Ward 7 and 8, in the MOB adjacent to our hospital, et cetera. But those practices are relocating and they are developing, but they are in different stages of development, and that takes some time. I think that has been the major issue in terms of the timing of the development of Cedar Hill. Structurally, I think we believe that all the things that we thought about, what would make this hospital successful are still there and will do so, just taking somewhat longer.

The other nuanced comment that I will make, and I think I made it last quarter as well as it relates to Cedar Hill, is that the arrangement we had with the district in entering the Cedar Hill partnership with the district was that they would build and essentially finance the construction of Cedar Hill. So, the absolute amounts of earnings, the absolute margins that we are going to have to achieve at Cedar Hill to get to our sort of target rates of return will be less than in those hospitals where we have built and invested the hundreds of millions of dollars to build the hospital.

As far as the facility in Palm Beach Gardens goes, I think that honestly, one of the biggest challenges we had at its opening was that we opened in the beginning of the summer, which is a difficult time to open, as you might imagine, in South Florida. It was not our original intent. We had originally planned to open earlier and take advantage of the busy season in Florida, but construction delays sort of made that impossible. I think by opening in the summertime, we got off to a bit of a slower start, but expect the facility, and I think again, in our prepared comments, we indicated the facility is getting better, volumes are increasing every month, and we expect that to accelerate as the busy season sort of ramps up in Florida over the next several months. I will reiterate the same comment.

No, structurally, I think everything we believed about the potential success of that hospital is still consistent with our original views, just taking a little bit longer to ramp up than we originally anticipated.

Thank you. Our next question comes from the line of Justin Lake of Wolfe Research. Your line is now open.

Thanks. Good morning. Just a couple numbers questions here. Steve, maybe you can break down the $80 million-$100 million of losses between those three facilities and Laurel Ridge in particular. What were the operating profits there when it was open? So we can get an idea of what it could recover to, and maybe Marc can give us any timeline he thinks within 2027 when you are thinking that might come back online. Thanks.

Yeah, we're confident that we're going to be back online sooner than later, but we don't have an exact date in 2027. We're still working with all the regulatory agencies. Things are going well. That will be back to where we were, we expect in 2027, but I can't give you an exact date. As far as the numbers go, Justin, when we first announced the loss of certification at Laurel Ridge, we disclosed that last year, the pre-tax income at that facility was in the $20 million-$25 million range. We've talked about incurring since it has lost its certification, but has continued to treat a small number of patients, that we expect it will lose $5 million or $10 million a quarter, each quarter that we remain open without certification. We've talked about Cedar Hill over the last several quarters, losing roughly $10 million a month.

As far as the Palm Beach Gardens Hospital, you can pretty much get that from looking at the difference between our same-store acute results and our acute care results. It lost about $15 million in this quarter. Expected to improve a little bit in Q4 and then continue to improve gradually from there.

Thank you. Our next question comes from the line of Matthew Gillmor of KeyBanc. Your line is now open.

Hey, thanks for the question. You called out labor as a positive factor in the quarter. I was hoping you could elaborate what you're seeing in terms of wage growth or turnover or use of contract labor.

Yeah. I think a little bit different story in the two segments. I think in the behavioral segment, we talked, over the course of several quarters, that we had sort of invested in, I am going to describe it as outsized headcount growth, because we have discussed, I think for quite some time, that in some of our behavioral facilities and markets, our volume growth was muted because of a constraint in staffing. Not enough nurses or therapists or the non-professional techs that are important to care in the behavioral segment. But as we have accomplished that, I think headcount growth has continued to decelerate. It decelerated in the third quarter. I think it rose by about 1.5%. I think going forward, headcount growth in the behavioral segment will largely be aligned with volume growth. That has been a benefit and an improvement in behavioral health segment.

I think in the acute segment, as your question sort of alluded to, we have seen a fairly significant reduction in temporary and traveling labor. I think that has risen, in the most recent quarter, by 3%, so it is well controlled. I think wage inflation has certainly come down from its heights during the pandemic to something in the 3%-3.5% range in both segments.

Got it. If I could follow up on the Talkspace acquisition. It sounds like you will share more on the fourth quarter call about the integration and synergy opportunity. I wanted to see if you would be willing to discuss, will there be synergies that you think that will pull through during the 2027 period, or is that a longer-term priority?

So, what we said originally, Matt, when we disclosed the Talkspace acquisition is that our expectation in the first 12 months of ownership, which would be into the third quarter of next year, was that the transaction would be slightly accretive. There is a very small amount of overhead and cost savings, sort of duplicative cost savings as we combine two public companies. But the vast majority of synergies are revenue synergies, and the opportunity that combining the lower acuity population, patient population that Talkspace has and the higher acuity patient population that UHS has really creates this robust continuum of care that really does not exist anywhere else in the behavioral space. That is the opportunity.

As far as the timing of it, I think we will begin to realize that, and we said this in our prepared remarks, in the first 12-24 months of ownership, so beginning in the back half of next year. As we, I think, noted in our remarks, I think we will be more specific about that and how much of that we have included in our guidance when we present guidance in February. But as Marc indicated in his remarks, we are certainly beginning to focus on those revenue synergies and create all the changes and policies and procedures and infrastructure and technology that we will need to execute on those synergies next year.

Thank you. Our next question comes from the line of Stephen Baxter, Wells Fargo. Your line is now open.

Hi. Thanks. I wanted to ask about the same store acute revenue per adjusted admission in the quarter. I guess, how should we think about what that figure would be if we were to exclude all change in year-over-year Medicaid supplemental, I guess just not just the out-of-period components? I guess, how did that compare to your expectations, and how much of a pressure is the surgical decline putting on those metrics? Thanks.

Yeah. So again, in the remarks, I think we called out three items that I think are putting pressure on that revenue per adjusted admission metric in the quarter. I think you ticked through them. One is the impact of the exchanges. While that is playing out, I think consistent with our expectations, it is certainly a drag compared to last year. Then there is the out-of-period DPP, which we talked about, and then the med surg mix pressure, which we talked about. We think the med surg mix pressure probably reduces the growth in revenue per adjusted admission by about 100 basis points. We think if we adjust for all three of those items, revenue per admission would have been up in the 3% range, which is within the range that we have talked about as the sustainable going forward range for pricing.

Okay. When you look at the improvement in acute volumes that you saw in the quarter, is there any meaningful difference in either geographic strength or different payer strengths you want to call out?

I think it is pretty broad-based geographically. We talked a little bit about payer mix in our remarks. I think Medicare is growing faster than the divisional average. Medicaid and commercial are both positive, but growing a little bit slower than the divisional average. We have seen an increase in self-pay or uncompensated care, largely sort of a one-for-one swap in the decline for exchanges.

I think the only other geographic note I would make, and it is probably more of a fourth quarter note, is that last year, we had a pretty soft fourth quarter in the Vegas market. They had a very light flu season in a year in which almost everybody else had a pretty acute flu season. So I think we are thinking about that as a bit of a tailwind for us in the fourth quarter. Otherwise, the strength in acute volumes has been pretty broad geographically.

Thank you. Our next question comes from the line of Kevin Fischbeck of BofA. Your line is now open.

Great. Thanks. I want to go back to your answer about the surgical volume coming in a little bit lower than what you guys were thinking about, and kind of attributing that to an acceleration of recent trends. What would you attribute that acceleration to, though? Is there something specific? Is it the IPO or is it something else? I am just trying to figure out how long this acceleration might last, and it would be better to understand what is causing it.

First, Kevin, I would say I do not think it is the inpatient-only dynamic. When we looked at the procedures covered by the inpatient-only regs, I think we concluded that most of our procedures that fall into those categories were procedures that had more than a two-midnight stay and appeared to us to be more acute than would allow them to really be transferred or evolved into outpatient procedures.

I do not know that I have a great explanation for exactly why we, and I think the industry in general, has seen this acceleration in certain procedures to outpatient. I will describe one of the challenges we see, and I will use GI as an example, is that as more and more GI procedures are being done outside of the hospital and largely in physician offices and in ASCs, we have found it difficult even to get GIs to cover our emergency rooms.

We either cannot get them to do it at all, or the expense of doing it and the cost of doing it is really sort of outsized. As a consequence, in some of our facilities, even our emergency room visits that are GI-related are being diverted to someplace else because we just do not have the coverage. I think there is a bit of a compounding effect that as more and more of these procedures, elective procedures, move into outpatient settings in some of these areas, and again, I think GI sort of stands out for us, even the emergency procedures that would have traditionally come to our emergency rooms are being diverted elsewhere.

Okay, great. I guess as one of the tailwinds that you mentioned in 2027, you just said the long-term growth algorithm. Can you just remind us that? I know that this year you are looking for 6.5% on acute and 3%-5% on behavioral. Is that what you are talking about? Or are you talking about something a little bit different?

No, I think in the last quarter, we sort of laid out our growth algorithms for the two segments. acute care, we are talking about 1.5%-2.5% adjusted admission growth. For the year, I think we are averaging slightly above that, I think 2.6% for the year, and then 2%-3% pricing growth. As I mentioned in my previous response, we believe if you sort of adjust for all these exogenous factors, we are running at around that 3% in the quarter, so at the low end of that range. On the behavioral side, we modified our growth algorithm, our adjusted patient day growth algorithm, to 1%-2% last quarter. And I think we are running for the year in the 1.7% range, so kind of towards the higher end of that range. Then 2%-3% pricing in behavioral, and I think we are running within that range in behavioral as well.

Thank you. Our next question comes from the line of Craig Hettenbach of Morgan Stanley. Your line is now open.

Yes, thank you. Just following up on Talkspace and understanding it is recently closed, but if you can just give some context of how that business is performing, growth rates you expect. Then as a follow-up on that, you mentioned the unique offering across mental health. How are you thinking about that in terms of implications of payer relationships on a longer-term basis as the strategy unfolds?

This is Marc. As we are integrating Talkspace, one of the big things when we talk about the continuum, Talkspace was acquiring patients in a distinct way, having nothing to do with patients coming from behavioral health settings, primarily. That opportunity now exists for us to send patients, refer patients over to Talkspace who are already in our ecosystem, whether in our outpatient settings or in our inpatient settings. Conversely, we have an opportunity now, and we are just starting to see this, where there are patients that are in that Talkspace ecosystem, that if they need further care, a higher level of care, they are getting directly referred now to us.

Within our own system here. Those opportunities did not exist on either end previously. They exist now. And we are just starting to see some of that come to fruition. I cannot give you exact numbers yet, but we feel like we are off to a good start. The Talkspace folks have been very encouraged by the way that this has been set up thus far. Again, we are only into this for a few months, but the teams are working very well together. We are very optimistic going forward that this is going to make a real difference for us and for their business.

Helpful. Thank you. Then just maybe just following on to that, as you think about what you have today, how you think about just organic in terms of the outpatient push, and then maybe even other tuck-ins around kind of virtual, more broadly.

Yeah. Look, we've always had a robust outpatient business, especially with our intensive outpatients, some of our partial hospitalization programs. But we're trying to expand even those in some of our locations where we didn't have it at all, or we didn't have it as much. We're certainly focused on that. We also have what we've talked about in previous quarters, Thousand Branches, which has been a newer effort in the last couple of years to expand into different areas in outpatient. That's been going well. And we see further opportunities on the horizon to continue that expansion. As far as other tuck-ins, other acquisitions, we're constantly looking. We're contacted often about that, and if something makes sense price-wise, we'll certainly pursue it. But right now, I think that we're moving in the right direction in the areas that I just mentioned.

Thank you. Our next question comes from the line of Jason Cassorla of Guggenheim Securities. Your line is now open.

Great. Thanks. Good morning. Wanted to ask about behavioral. Obviously strong volume up 2.1%, same facility revenue up 4%, excluding out of period supplemental same facility EBITDA was only effectively flat. I guess, can you help in terms of the disconnect on the EBITDA growth side? Is that almost entirely explained by Laurel Ridge and same facility EBITDA growth or behavioral would have otherwise been in line with revenue growth or are there puts and takes there? Thanks.

No, I think, Jason, to a large degree you've answered your own question. I think that Laurel Ridge is probably the single biggest drag on the behavioral earnings improvement. Beyond that, as I said earlier, as we think about revenue growth from a volume pricing perspective, I think we're running towards the high end of our range for expected volumes. Towards the lower end of our range in pricing, I think some of that is a reflection of the fact that over the last several years, pricing has been very robust. Some of that has been the benefit of DPP, but even when you exclude that, our pricing and our contractual pricing has been very robust as we've been getting contractual price increases from payers, particularly Managed Medicaid payers who had not given us increases for several years.

Unfortunately, obviously, after several years of that, we've started to anniversary some of that benefit and the pricing, I think, has been moved into that 2%-3% range. But I think we're fairly confident that we'll be able to sustain that, and as we go into next year, those comparisons will become easier.

Got it. Thanks. Very helpful. Maybe just as a follow-up, I wanted to ask about the $10 million Medicaid supplemental headwind that you flagged for the fourth quarter of 2027. Maybe could you just expand on how you're thinking about that estimate or which state programs are impacted in that quarter? I know that the rules out there are still proposed, but just any other color related to that fourth quarter 2027 headwind, and then any updates you may have around the potential SDP, and provider tax headwinds from 2028 and beyond would be helpful. Thanks.

Yeah. So, as far as the headwinds in 2028 and beyond, we've been disclosing those estimates in our SEC filings really since the passage of OB-3. We'll update those with our current filing. But they shouldn't be terribly different from what we've been disclosing to date. As far as the $10 million specific headwind in the fourth quarter of 2027, Jason, I don't have that detail in front of me, but happy to discuss that offline at some point.

Thank you. Our next question comes from the line of Andrew Mok of Barclays. Your line is now open.

Hi, good morning. Just wanted to follow up on the acute dynamics in the quarter. Acute volumes were very strong, but med surg mix was negative and weighed on acute pricing. How does the management team internalize this? Are you comfortable trading mix and price for stronger volumes, or does this lead you to reconsider elements of your strategy? Thanks.

The answer, Andrew, is that's not a sort of conscious swap on our part. We didn't make a conscious decision to increase volumes but decrease procedural volumes. Most of our medical volumes honestly come through the emergency room. So those are patients who come to us. Procedural volumes tend to be more elective. We have done a lot of things to continue to build on procedural volumes, including investments in technology and things like robotics and things like OR capacity, et cetera. That's paid off in the service lines that we mentioned earlier.

The other issue, I think, is, and I think Marc talked about in his prepared remarks, we continue to try and increase our outpatient access points. That includes things like FEDs, freestanding emergency departments, it includes physician offices. All those things are designed to create more referrals into our procedural volumes. Attempting to do that as well. Again, I would just emphasize the fact that we're looking to do both, to grow volumes overall, but also absolutely to grow surgical and procedural volumes to the extent that we can. We're not making a choice of medical admissions over surgical admissions.

Thank you. Our next question comes from the line of Ben Hendrix of RBC Capital Markets. Your line is now open.

Great. Thank you very much. As we get past the de novo ramp and the Talkspace integration, I think you noted that CapEx would normalize down to an $800 million range. It seems like that's getting closer to maintenance levels, but are there any kind of development priorities you would rank order going forward, following the integrations and de novo ramps? I mean, would you be focusing on further build-out of behavioral capabilities versus acute service lines versus tech and AI development? How would you think about your priorities there? Thanks.

Yeah. I would just clarify a little bit, Ben, your comment. As we go from $1 billion a year roughly that we've been spending on CapEx to $800 million going forward, that's largely because these large de novo projects that we've had over the last several years, the Palm Beach Gardens Hospital, the Riverside County, California replacement facility, West Henderson. We don't really have any full-scale de novo projects, and that's largely contributing to the decline. You characterized $800 million as maintenance capital. I think that's a bit of an exaggeration. We sort of, I think, consider maybe 2% of our revenues to be devoted to maintenance capital. So something in that $250 million-$300 million range. So there's another $400 million, $500 million, $550 million of expansionary capital in the $800 million. And that's new capacity, new beds, new ORs, new ERs, robotics in acute care segment.

I think an emphasis on, and we've touched on this in other ways in our comments here, an emphasis on outpatient growth and outpatient access points in both of the segments. Yeah, I think the primary driver of the decline is just not having any of these big de novo projects in the pipeline over the next several years. But it certainly doesn't indicate an unwillingness on our part to continue to reinvest in the business strategically in the areas that we think will drive growth in the future.

Thank you. Our next question comes from the line of Scott Fidel, Goldman Sachs. Your line is now open.

Hi. Thanks. Good morning. First question, appreciate the details that you gave us on the anticipated state directed payments headwind. Would you be able to break that out between the mix of that acute care and behavioral?

Scott, I think what we've said historically is that the SDP payments are split pretty evenly between the two segments. I think the reductions are similarly split.

Okay. Then, would be interested in an update on the health plan, the Medicare Advantage plan, which you guys have been growing it pretty impressively the last couple of years, and it's getting quite sizable. Can you just talk about how the MLR trends in the business have been going this year, and then in terms of your bids for 2027, how you position those relative to growth first margins? Thanks.

Yeah. You described the health plan as an MA plan. It is largely an MA plan. About 90% of its revenue comes from MA, but it does have about a 10% commercial mix as well. We talked about in 2026, a $25 million, roughly, tailwind from improvements at the health plan, and I think we are largely tracking to that. I think next year, there'll be sort of the normal amount of growth as the revenue has grown, but not expecting a material impact up or down in terms of our earnings in 2027 as a result of the health plan. Obviously, the health plan, from our perspective, continues to provide a significant benefit to acute care hospitals. We operate the plan only in those markets in which we acute care hospitals.

Steve, could you just on the margins, just where you view the MA pre-tax margin now after getting that $25 million improvement in the underlying earnings, and that is it for me. Thanks.

Yeah. We think that historically the plan has operated with either low negative single-digit margins or low positive single-digit margins. I think the improvement from last year is because the plan is operating in low positive single digit margins, and I think that is our expectation that it will continue to do so over the next couple of years.

Thank you. Our next question will come from the line of Benjamin Rossi of JPMorgan. Your line is now open.

Hey, good morning. Thanks for taking my question. I have heard you describe a few offset opportunities in recent quarters related to your payer mixing initiatives, your outpatient network development across segments, some of your technology investments, and then some of your expense initiatives or things like supplies. I know you are not providing formal 2027 commentary, but could you walk us through how those initiatives are coming together and where you expect to see contribution to margins in the coming quarters?

Yeah. Ben, look, I think you have done a decent job of framing your question around the things that we have already discussed. As we think about the challenges that will come, especially from OB-3 in the next few years, whether that is Medicaid work requirements in 2027 and 2028 or the Medicaid supplemental reductions mostly in 2028 and beyond. A number of things that we are trying to address.

Technology developments, we have talked in previous quarterly calls about the things that we are doing in revenue cycle to improve revenue cycle performance. We had a very large third-party consulting exercise in acute care revenue cycle in the last 18 months or so. We are undergoing a similar exercise in behavioral, developing technology, AI, and otherwise, to help us do that, developing technology, AI, and otherwise, to help us control length of stay, better control length of stay in acute care.

I think you alluded to this in your question, a lot of the outpatient emphasis in behavioral, whether that is Talkspace or Thousand Branches or just the efforts within our existing facilities, really have the double benefit of meeting demand where patients are looking for it in the outpatient setting. But it also, as we build outpatient, we are really shifting our payer mix away from Medicaid and more to commercial and Medicare because that is where we think the growth is, and that helps us avoid some of these Medicaid cuts. So doing all those things, again, in terms of their specific impact and their specific impact in 2027, I think we will provide more color on that in February.

Steven, I think we have time for one more question.

Universal Health Services (UHS) Q3 2026 Earnings Call Transcript

Company Participants